XML 32 R14.htm IDEA: XBRL DOCUMENT
v3.24.1

Note 8 - OMIDRIA Royalty Obligation | 12 Months Ended
--- | ---
Dec. 31, 2023
Notes to Financial Statements |
Royalty Obligation [Text Block] | Note 8—OMIDRIA Royalty Obligation In September 2022, we sold to DRI an interest in our future OMIDRIA royalty receipts and received $125.0 million in cash consideration which was recorded as an OMIDRIA royalty obligation on our consolidated balance sheet. DRI is entitled to receive royalties on OMIDRIA net sales between September 1, 2022 and December 31, 2030, subject to annual caps. DRI receives their prorated monthly cap amount before we receive any royalty proceeds. DRI is not entitled to carry-forward nor recoup any shortfall if the royalties paid by Rayner for an annual period are less than the cap amount applicable to each discrete calendar year. Additionally, DRI has no recourse to or security interest in our assets other than our OMIDRIA royalty receipts. The changes in the OMIDRIA royalty obligation during the year ended December 31, 2023 are as follows (in thousands):
Balance at December 31, 2022 |  | $ | 126,278 |
Principal payments |  |  | (1,152 | )
Balance at December 31, 2023 |  | $ | 125,126 |
The OMIDRIA royalty obligation is classified as a Level 3 liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. As of December 31, 2023, the approximate fair value of our obligation was $116.3 million. For the years ended December 31, 2023 and December 31, 2022, we incurred interest expense of $11.8 million and $2.9 million, respectively, on the OMIDRIA royalty obligation. As of December 31, 2023, the maximum scheduled principal and interest payments (based on an implied effective interest rate of 9.4%) are as follows:
|  |  |  |  |  |  |  |  |  | Total |
|  | Principal |  |  | Interest |  |  | Annual Cap |
|  | (In thousands) |
2024 |  | $ | 8,576 |  |  | $ | 11,424 |  |  | $ | 20,000 |
2025 |  |  | 14,641 |  |  |  | 10,359 |  |  |  | 25,000 |
2026 |  |  | 16,081 |  |  |  | 8,919 |  |  |  | 25,000 |
2027 |  |  | 17,664 |  |  |  | 7,336 |  |  |  | 25,000 |
2028 |  |  | 19,402 |  |  |  | 5,598 |  |  |  | 25,000 |
Thereafter |  |  | 48,762 |  |  |  | 4,988 |  |  |  | 53,750 |
Total scheduled payments |  | $ | 125,126 |  |  | $ | 48,624 |  |  | $ | 173,750 |
Subsequent Event In February 2024, Omeros and DRI expanded their royalty purchase agreement, resulting in Omeros receiving $115.5 million in cash consideration from DRI upon closing. The Amended and Restated Royalty Purchase Agreement ("RPA") eliminated the caps on royalty payments effective in the first quarter of 2024 and provides that DRI will now receive all royalties on U.S. net sales of OMIDRIA payable between January 1, 2024 and December 31, 2031. DRI is entitled to payment only to the extent of royalty payments that are payable in the respect of U.S. net sales of OMIDRIA on or before December 31, 2031 and DRI has no recourse to our assets other than its interest in OMIDRIA royalties. Omeros retains the right to receive all royalties payable by Rayner on any net sales of OMIDRIA outside the U.S. payable from and after January 1, 2024, as well as royalties on global net sales of OMIDRIA payable from and after December 31, 2031. To date, international royalties have not been significant. We are also entitled to receive a milestone ranging between $10.0 million and $27.5 million if U.S. net sales of OMIDRIA reach applicable thresholds ranging between a total of $156.0 million and $160.0 million for any period of four consecutive quarters prior to January 1, 2026. In addition, we are entitled to receive a separate milestone ranging between $8.0 million and $27.5 million if U.S. net sales of OMIDRIA reach applicable thresholds ranging between a total of $181.0 million and $185.0 million for any period of four consecutive quarters prior to January 1, 2028.

X
- Definition Disclosure of the company's royalty obligation. + References No definition available. + Details
Name: | omer_RoyaltyObligationTextBlock
Namespace Prefix: | omer_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration